The startup operates a contract research organization that provides preclinical drug discovery screening services, specializing in electrophysiology assays for medicinal chemistry support. Their flexible business models, including fee-for-service and collaborative options, enable clients to access tailored solutions for cardiac safety profiling, neuroscience, and translational assays.
Funding
$9.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery and development requires robust preclinical screening to identify and optimize drug candidates, particularly for ion channel modulators. Traditional methods can be costly and time-consuming, hindering efficient progress towards clinical development.
Solution
Metrion Biosciences operates as a contract research organization (CRO), providing specialized preclinical drug discovery services focused on ion channel screening, cardiac safety, and neuroscience. They offer tailored solutions, including assay development, high-throughput screening, and detailed characterization of lead compounds. Metrion utilizes electrophysiology and fluorescence-based platforms to deliver high-quality data, supporting medicinal chemistry optimization, cardiac safety profiling, and neuroscience research. Their integrated drug discovery services aim to de-risk ion channel modulators, guiding programs toward clinical development with expertise in translational biology, ADMET, and DMPK.
Target Audience
Metrion Biosciences serves pharmaceutical and biotechnology companies, ranging from large pharmaceutical organizations to specialist businesses and academic institutions, seeking preclinical drug discovery services, particularly those focused on ion channels.
Features
- Ion channel screening services using automated electrophysiology and fluorescence-based assays
- Cardiac safety screening, including GLP hERG testing and CiPA screening
- Neuroscience services, including native neuronal ion channel assays and central/peripheral neuronal firing assays
- Integrated drug discovery services, combining ion channel biology, medicinal chemistry, and translational biology
- Custom assay development and validation for specific targets
- High-throughput screening capabilities for early-stage compound screening and lead optimization
- Detailed characterization of lead compounds in human cells and native tissues
- Translational services, including confirmation of efficacy in stem cell-derived and other phenotypic models
- Access to a high-quality small molecule library for hit identification